DFWHC Associate Member Xenex awarded for Visionary Innovation Leadership


Based on a recent analysis of healthcare room disinfection, Frost & Sullivan recognized Xenex Disinfection Services with the 2017 Global Frost & Sullivan Award for Visionary Innovation Leadership on May 24.

The Xenex LightStrike™ Germ-Zapping Robot™ is a portable, no-touch device capable of helping healthcare facilities bring down infection rates by destroying the pathogens that cause them. LightStrike robots deactivate microorganisms, including Clostridium difficile (C. diff.), rapidly and cost effectively to reduce the risk of hospital-acquired infections (HAIs).

“While most companies in the hospital disinfection space offer single-spectrum mercury ultraviolet (UV) systems or hydrogen peroxide-based disinfection systems, Xenex’s UV disinfection system sets itself apart via its use of xenon, an environmentally-friendly inert gas, to create UV-C light,” said Frost & Sullivan Industry Analyst Brahadeesh Chandrasekaran. “Pulsed xenon UV light is significantly more intense than mercury UV systems and covers the entire germicidal spectrum. And while some Xenex customers report disinfecting dozens of rooms per day with a single device, we were most impressed with the hospitals that have reported 50-100 percent reductions in their infection rates after using the LightStrike robots.”

Xenex LightStrike robots are the only UV technology to be credited by hospitals in multiple peer reviewed and published outcome studies for their role in helping hospitals reduce infection rates. Xenex devices provide disinfection alternatives with their quick and proven infection reduction results. The device has been in use for more than five years with no reported materials damage.

Xenex devices are used in more than 400 hospitals, surgery centers and long-term acute care facilities in the U.S., Europe, Canada, Japan, UK and Africa. In terms of unit adoption, the company has been growing at more than 50 percent year on year and the demand from healthcare facilities in the U.S., Japan and Europe is set to increase with more stringent infection control protocols.

“Being honored for our innovation by a highly-respected organization like Frost & Sullivan is a huge honor,” said Dr. Mark Stibich, Xenex co-founder and Chief Scientific Officer. “Every day we talk to our hospitals and when they report seeing reductions in their infection rates after investing in a Xenex LightStrike infection prevention program, it’s incredibly rewarding. We greatly appreciate that Frost & Sullivan recognizes the scientific differences that set Xenex apart in the disinfection industry.”

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive research to identify best practices in the industry.